FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2944028170> ?p ?o ?g. }

• W2944028170 endingPage "111" @default.
• W2944028170 startingPage "103" @default.
• W2944028170 abstract "Children with Hutchinson-Gilford progeria syndrome (HGPS), a rare premature aging disease, exhibit extraskeletal calcifications detected by radiographic analysis and on physical examination. The aim of this study was to describe the natural history and pathophysiology of these abnormal calcifications in HGPS, and to determine whether medications and/or supplements tested in clinical trials alter their development.Children from two successive clinical trials administering 1) lonafarnib (n = 26) and 2) lonafarnib + pravastatin + zoledronic acid (n = 37) were studied at baseline (pre-therapy), one year on therapy, and at end-of-therapy (3.3-4.3 years after the baseline visit). Calcium supplementation (oral calcium carbonate) was administered during the first year of the second trial and was subsequently discontinued. Information on calcifications was obtained from physical examinations, radiographs, and serum and urinary biochemical measures. The mineral content of two skin-derived calcifications was determined by x-ray diffraction.Extraskeletal calcifications were detected radiographically in 12/39 (31%) patients at baseline. The odds of exhibiting calcifications increased with age (p = 0.045). The odds were unaffected by receipt of lonafarnib, pravastatin, and zoledronate therapies. However, administration of calcium carbonate supplementation, in conjunction with all three therapeutic agents, significantly increased the odds of developing calcifications (p = 0.009), with the odds plateauing after the supplement's discontinuation. Composition analysis of calcinosis cutis showed hydroxyapatite similar to bone. Although serum calcium, phosphorus, and parathyroid hormone (PTH) were within normal limits at baseline and on-therapy, PTH increased significantly after lonafarnib initiation (p < 0.001). Both the urinary calcium/creatinine ratio and tubular reabsorption of phosphate (TRP) were elevated at baseline in 22/39 (56%) and 31/37 (84%) evaluable patients, respectively, with no significant changes while on-therapy. The mean calcium × phosphorus product (Ca × Pi) was within normal limits, but plasma magnesium decreased over both clinical trials. Fibroblast growth factor 23 (FGF23) was lower compared to age-matched controls (p = 0.03).Extraskeletal calcifications increased with age in children with HGPS and were composed of hydroxyapatite. The urinary calcium/creatinine ratio and TRP were elevated for age while FGF23 was decreased. Magnesium decreased and PTH increased after lonafarnib therapy which may alter the ability to mobilize calcium. These findings demonstrate that children with HGPS with normal renal function and an unremarkable Ca × Pi develop extraskeletal calcifications by an unidentified mechanism that may involve decreased plasma magnesium and FGF23. Calcium carbonate accelerated their development and is, therefore, not recommended for routine supplementation in these children." @default.
• W2944028170 created "2019-05-16" @default.
• W2944028170 creator A5002509939 @default.
• W2944028170 creator A5006471805 @default.
• W2944028170 creator A5027561648 @default.
• W2944028170 creator A5029213839 @default.
• W2944028170 creator A5032300440 @default.
• W2944028170 creator A5033229659 @default.
• W2944028170 creator A5034509516 @default.
• W2944028170 creator A5060208068 @default.
• W2944028170 creator A5062691997 @default.
• W2944028170 creator A5074474395 @default.
• W2944028170 creator A5078958915 @default.
• W2944028170 creator A5085709549 @default.
• W2944028170 creator A5088267373 @default.
• W2944028170 date "2019-08-01" @default.
• W2944028170 modified "2023-10-15" @default.
• W2944028170 title "Extraskeletal Calcifications in Hutchinson-Gilford Progeria Syndrome" @default.
• W2944028170 cites W1030286136 @default.
• W2944028170 cites W1964551999 @default.
• W2944028170 cites W1980190724 @default.
• W2944028170 cites W2001418129 @default.
• W2944028170 cites W2014274964 @default.
• W2944028170 cites W2016268789 @default.
• W2944028170 cites W2024153799 @default.
• W2944028170 cites W2044636142 @default.
• W2944028170 cites W2056537785 @default.
• W2944028170 cites W2073460054 @default.
• W2944028170 cites W2075168676 @default.
• W2944028170 cites W2085977362 @default.
• W2944028170 cites W2089858094 @default.
• W2944028170 cites W2094862767 @default.
• W2944028170 cites W2105530378 @default.
• W2944028170 cites W2112343383 @default.
• W2944028170 cites W2128180309 @default.
• W2944028170 cites W2133514604 @default.
• W2944028170 cites W2136482074 @default.
• W2944028170 cites W2139626526 @default.
• W2944028170 cites W2143185290 @default.
• W2944028170 cites W2143921117 @default.
• W2944028170 cites W2208579015 @default.
• W2944028170 cites W2215626906 @default.
• W2944028170 cites W2233927503 @default.
• W2944028170 cites W2293273525 @default.
• W2944028170 cites W2320429729 @default.
• W2944028170 cites W2325488219 @default.
• W2944028170 cites W2361426002 @default.
• W2944028170 cites W2465571069 @default.
• W2944028170 cites W2526717031 @default.
• W2944028170 cites W2623204745 @default.
• W2944028170 cites W2783887361 @default.
• W2944028170 cites W2792203963 @default.
• W2944028170 cites W2792358194 @default.
• W2944028170 cites W2810324863 @default.
• W2944028170 doi "https://doi.org/10.1016/j.bone.2019.05.008" @default.
• W2944028170 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6628204" @default.
• W2944028170 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31077852" @default.
• W2944028170 hasPublicationYear "2019" @default.
• W2944028170 type Work @default.
• W2944028170 sameAs 2944028170 @default.
• W2944028170 citedByCount "5" @default.
• W2944028170 countsByYear W29440281702020 @default.
• W2944028170 countsByYear W29440281702022 @default.
• W2944028170 crossrefType "journal-article" @default.
• W2944028170 hasAuthorship W2944028170A5002509939 @default.
• W2944028170 hasAuthorship W2944028170A5006471805 @default.
• W2944028170 hasAuthorship W2944028170A5027561648 @default.
• W2944028170 hasAuthorship W2944028170A5029213839 @default.
• W2944028170 hasAuthorship W2944028170A5032300440 @default.
• W2944028170 hasAuthorship W2944028170A5033229659 @default.
• W2944028170 hasAuthorship W2944028170A5034509516 @default.
• W2944028170 hasAuthorship W2944028170A5060208068 @default.
• W2944028170 hasAuthorship W2944028170A5062691997 @default.
• W2944028170 hasAuthorship W2944028170A5074474395 @default.
• W2944028170 hasAuthorship W2944028170A5078958915 @default.
• W2944028170 hasAuthorship W2944028170A5085709549 @default.
• W2944028170 hasAuthorship W2944028170A5088267373 @default.
• W2944028170 hasBestOaLocation W29440281702 @default.
• W2944028170 hasConcept C104317684 @default.
• W2944028170 hasConcept C126322002 @default.
• W2944028170 hasConcept C126894567 @default.
• W2944028170 hasConcept C134018914 @default.
• W2944028170 hasConcept C185592680 @default.
• W2944028170 hasConcept C2775981168 @default.
• W2944028170 hasConcept C2778465436 @default.
• W2944028170 hasConcept C2780309369 @default.
• W2944028170 hasConcept C55493867 @default.
• W2944028170 hasConcept C71924100 @default.
• W2944028170 hasConcept C90924648 @default.
• W2944028170 hasConceptScore W2944028170C104317684 @default.
• W2944028170 hasConceptScore W2944028170C126322002 @default.
• W2944028170 hasConceptScore W2944028170C126894567 @default.
• W2944028170 hasConceptScore W2944028170C134018914 @default.
• W2944028170 hasConceptScore W2944028170C185592680 @default.
• W2944028170 hasConceptScore W2944028170C2775981168 @default.
• W2944028170 hasConceptScore W2944028170C2778465436 @default.
• W2944028170 hasConceptScore W2944028170C2780309369 @default.
• W2944028170 hasConceptScore W2944028170C55493867 @default.

• next